This content is in French.
Radium-223 & Enzalutamide: A Powerful Duo Against mCRPC!
6 février 2025
#Oncology #ProstateCancer #mCRPC #Radium223 #Enzalutamide #CombinationTherapy #Immunotherapy #NuclearMedicine
Castration-resistant prostate cancer (mCRPC) is one of the most advanced and aggressive stages of the disease. Tumors become insensitive to androgen deprivation and continue to grow despite low testosterone levels. Bone metastases, a hallmark of mCRPC, cause severe complications that impact both patients' quality of life and clinical management. The morbidity associated with current treatment resistance remains high.
Castration-resistant prostate cancer (mCRPC) is one of the most advanced and aggressive stages of the disease. Tumors become insensitive to androgen deprivation and continue to grow despite low testosterone levels. Bone metastases, a hallmark of mCRPC, cause severe complications that impact both patients' quality of life and clinical management. The morbidity associated with current treatment resistance remains high.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Shore, N., et al. (2024). Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer. Frontiers in medicine, 11, 1460212
View the source
